2. Signaling Pathways
  3. MAPK/ERK Pathway
  4. Ribosomal S6 Kinase (RSK)
  5. p70S6K Isoform
  6. p70S6K Inhibitor

p70S6K Inhibitor

p70S6K Inhibitors (12):

Cat. No. Product Name Effect Purity
  • HY-15773
    PF-4708671
    		Inhibitor 99.85%
    PF-4708671 is a potent cell-permeable S6K1 inhibitor with a Ki of 20 nM and IC50 of 160 nM.
  • HY-12493A
    LY-2584702 tosylate salt
    		Inhibitor 98.58%
    LY-2584702 tosylate salt is a selective ATP competitive inhibitor of p70S6K with an IC50 of 4 nM. In S6K1 enzyme assay, the IC50 of LY-2584702 is 2 nM.
  • HY-12059
    AT7867
    		Inhibitor 99.88%
    AT7867 is a potent ATP-competitive inhibitor of Akt1/Akt2/Akt3 and p70S6K/PKA with IC50s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.
  • HY-16071
    AT13148
    		Inhibitor 99.21%
    AT13148 is an orally active and ATP-competitive, multi-AGC kinase inhibitor with IC50s of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively.
  • HY-100501
    M2698
    		Inhibitor 99.87%
    M2698 (MSC2363318A) is an orally active, ATP competitive, selective p70S6K and Akt dual-inhibitor with IC50s of 1 nM for p70S6K, Akt1 and Akt3. M2698 can cross the blood-brain barrier and has anti-cancer activity.
  • HY-101963
    AD80
    		Inhibitor 99.88%
    AD80, a multikinase inhibitor, inhibits RET, RAF,SRCand S6K, with greatly reduced mTOR activity.
  • HY-12059A
    AT7867 dihydrochloride
    		Inhibitor 99.75%
    AT7867 dihydrochloride is a potent ATP-competitive inhibitor of Akt1/Akt2/Akt3 and p70S6K/PKA with IC50s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.
  • HY-157133
    TAS0612
    		Inhibitor 98.70%
    TAS0612 is an orally novel inhibitor of RSK、AKT and S6K. TAS0612 has broad-spectrum activity against tumor models via inhibiting cell growth.
  • HY-18313
    S6K1-IN-1
    		Inhibitor 99.44%
    S6K-18 is a potent and selective p70S6K1 inhibitor with an IC50 of 52 nM.
  • HY-N2357
    Eudesmin
    		Inhibitor 99.96%
    Eudesmin ((-)-Eudesmin) impairs adipogenic differentiation via inhibition of S6K1 signaling pathway. Eudesmin possesses diverse therapeutic effects, including anti-tumor, anti-inflammatory, and anti-bacterial activities.
  • HY-W011109
    CKI-7
    		Inhibitor
    CKI-7 is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM. CKI-7 is a selective Cdc7 kinase inhibitor. CKI-7 also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 has a much weaker effect on casein kinase II and other protein kinases.
  • HY-120035
    DD1
    		Inhibitor 99.40%
    DD1, a proteasome inhibitor, targets Bax activation and P70S6K degradation during acute myeloid leukemia (AML) apoptosis. DD1 induces apoptosis in the caspase-dependent manner. DD1 induces mitochondrial membrane depolarization and Bad dephosphorylation.